Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomecompanyKANAMYCIN SULFATE CAS:70560-51-9
KANAMYCIN SULFATE
KANAMYCIN SULFATE

KANAMYCIN SULFATE CAS:70560-51-9

Price USD55.00
Packge 1KG
  • Min. Order:1KG
  • Supply Ability:1000KG
  • Time:2022-06-06

Product Details

  • Product NameKANAMYCIN SULFATE
  • CAS No.70560-51-9
  • EINECS No.684-844-0
  • MFC18H38N4O15S
  • MW582.58
  • Appearancepowderwhite to off-white
  • storage temp. 2-8°C
storage temp. 2-8°C
solubility H2O: 10-50 mg/mL As a stock solution. Stock solutions should be stored at 2-8°C. Stable at 37°C for 5 days.
form powder
color white to off-white
BRN 3874279
CAS DataBase Reference70560-51-9(CAS DataBase Reference)
Clinical UseKanamycin Sulfate was isolated in 1957 by Umezawaand coworkers from Streptomyces kanamyceticus. Its activityagainst mycobacteria and many intestinal bacteria, aswell as several pathogens that show resistance to other antibiotics,brought a great deal of attention to this antibiotic.As a result, kanamycin was tested and released for medicaluse in a very short time.
The use of kanamycin in the United States usually is restrictedto infections of the intestinal tract (e.g., bacillarydysentery) and to systemic infections arising from Gramnegativebacilli (e.g., Klebsiella, Proteus, Enterobacter, andSerratia spp.) that have developed resistance to other antibiotics.It has also been recommended for preoperative antisepsisof the bowel. It is absorbed poorly from the intestinaltract; consequently, systemic infections must be treated byintramuscular or (for serious infections) intravenous injections.These injections are rather painful, and the concomitantuse of a local anesthetic is indicated. The use ofkanamycin in the treatment of TB has not been widely advocatedsince the discovery that mycobacteria develop resistancevery rapidly. In fact, both clinical experience andexperimental work indicate that kanamycin developscross-resistance in the tubercle bacilli with dihydrostreptomycin,viomycin, and other antitubercular drugs. Like streptomycin,kanamycin may cause decreased or complete lossof hearing. On development of such symptoms, its useshould be stopped immediately.


Company Profile Introduction

-
  • Since:2018-09-06
  • Address: Room B801, Financial Plaza, Jintai District, Baoji, Shaanxi, CN
INQUIRY